Q'Apel Medical Welcomes Stewart Strong as New CEO to Drive Future Growth
On July 1, 2025, Q'Apel Medical, a key player in the field of neurovascular interventions, proudly announced the appointment of Stewart Strong as its new President and Chief Executive Officer. With over two decades of experience in the medical technology sector, Strong is well-equipped to propel the company into its forthcoming growth phase.
R. King Nelson, Chairman of the Board, heralded Strong's appointment, stating, "Stew is the right person at the right time to lead Q'Apel through our next phase of growth." Nelson emphasized Strong's unparalleled passion for steering high-performing teams and crafting commercial strategies that ensure sustainable growth. This leadership comes at a crucial time as Q'Apel seeks to bolster its commercial performance, particularly within the United States, alongside enhancing its global reach.
Before joining Q'Apel Medical, Strong served as the Global President of the Hospital Business Unit at Haemonetics. His tenure there was marked by significant achievements, transforming the unit into a global powerhouse by establishing a world-class commercial organization and driving revenues up by threefold. Previously, he also held the reins as President of the Teleflex Interventional franchise, focusing on increasing the company’s foothold in interventional cardiology and radiology.
With a diverse background that includes executive roles at leading companies such as Vidacare and AtriCure, as well as involvement on boards for innovative firms like Vivasure Medical, Strong brings a wealth of expertise to Q'Apel Medical.
In his own words, Strong expressed enthusiasm about stepping into this pivotal role. "I am honored to assume this position and excited to get started. Q'Apel is a leader in the neurovascular space, recognized for driving innovation and its customer-centricity," he said. He looks forward to collaborating closely with the Board of Directors and the broader Q'Apel team to cultivate growth and harness the full potential of the company’s capabilities.
Q'Apel Medical is committed to revolutionizing neurovascular interventions. Their mission is driven by understanding and meeting customer needs through innovative solutions that tackle the most complex clinical challenges. The organization focuses on developing high-quality, engineered products specifically designed in concert with neurovascular specialists who understand what is necessary now while being versatile about future demands.
In closing, the announcement of Stewart Strong as CEO is an exciting development for Q'Apel Medical, as the company is poised to continue its innovative journey and further solidify its position in the medical device industry. As they embark on this new chapter, the groundwork has been laid for a bright future in neurovascular solutions, making it a company to watch closely in the upcoming years.
R. King Nelson, Chairman of the Board, heralded Strong's appointment, stating, "Stew is the right person at the right time to lead Q'Apel through our next phase of growth." Nelson emphasized Strong's unparalleled passion for steering high-performing teams and crafting commercial strategies that ensure sustainable growth. This leadership comes at a crucial time as Q'Apel seeks to bolster its commercial performance, particularly within the United States, alongside enhancing its global reach.
Before joining Q'Apel Medical, Strong served as the Global President of the Hospital Business Unit at Haemonetics. His tenure there was marked by significant achievements, transforming the unit into a global powerhouse by establishing a world-class commercial organization and driving revenues up by threefold. Previously, he also held the reins as President of the Teleflex Interventional franchise, focusing on increasing the company’s foothold in interventional cardiology and radiology.
With a diverse background that includes executive roles at leading companies such as Vidacare and AtriCure, as well as involvement on boards for innovative firms like Vivasure Medical, Strong brings a wealth of expertise to Q'Apel Medical.
In his own words, Strong expressed enthusiasm about stepping into this pivotal role. "I am honored to assume this position and excited to get started. Q'Apel is a leader in the neurovascular space, recognized for driving innovation and its customer-centricity," he said. He looks forward to collaborating closely with the Board of Directors and the broader Q'Apel team to cultivate growth and harness the full potential of the company’s capabilities.
Q'Apel Medical is committed to revolutionizing neurovascular interventions. Their mission is driven by understanding and meeting customer needs through innovative solutions that tackle the most complex clinical challenges. The organization focuses on developing high-quality, engineered products specifically designed in concert with neurovascular specialists who understand what is necessary now while being versatile about future demands.
In closing, the announcement of Stewart Strong as CEO is an exciting development for Q'Apel Medical, as the company is poised to continue its innovative journey and further solidify its position in the medical device industry. As they embark on this new chapter, the groundwork has been laid for a bright future in neurovascular solutions, making it a company to watch closely in the upcoming years.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.